Lymphoma
Lymphomas are a diverse group of hematologic malignancies that typically develops in lymph nodes and can originate from B cells, T cells, and natural killer cells. They are broadly divided into 2 categories, Hodgkin lymphoma and non-Hodgkin lymphoma.
Advertisement
Advertisement
Aggressive B-Cell Lymphoma
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Cema-cel is feasible and can induce durable responses in patients with LBCL, achieving an ORR of 58% and a CR rate of 42%.
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
An expert panel discusses utilizing molecular strategies to determine treatment decisions for DLBCL.
Hodgkin Lymphoma
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Resistance remains a challenge in central nervous system lymphoma, creating a need for novel therapeutic combinations.
The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors.
Grzegorz Nowakowski discusses the challenges and advances in central nervous system lymphoma treatment.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Indolent B-Cell Lymphoma
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Mantle Cell Lymphoma
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Dr. Phillips discussed the phase II TRIANGLE study, the shifting role of HSCT, and unmet needs in high-risk patients.
CAR22 therapy demonstrated an ORR of 100% and a complete response rate of 83% in six patients with MCL or FL.
T-Cell Lymphoma
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Based on promising results from the phase II TELLOMAK study, the FDA grants a breakthrough therapy designation for lacutamab.
Researchers have developed a new scoring system using one of the largest global cohorts of T-cell lymphoma patients.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.